GRCL Gracell Biotechnologies Inc. ADRs

Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$13.13  -0.11 (-0.83%)
As of 10/18/2021 15:59:50 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  
IPO date:  01/08/2021
Outstanding shares:  67,243,502
Average volume:  69,558
Market cap:   $919,891,107
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.43
PS ratio:   0.00
Return on equity:   -15.83%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy